Neurological Disorder Diagnostics Market, by Technology (Imaging, and In Vitro Diagnostics), by Disease Indication (Genetic Neurological Disorders, Immunological Neurological Disorders, Paraneoplastic Syndrome, Paraproteinemic Neuropathies, and Others), b

Neurological Disorder Diagnostics Market, by Technology (Imaging, and In Vitro Diagnostics), by Disease Indication (Genetic Neurological Disorders, Immunological Neurological Disorders, Paraneoplastic Syndrome, Paraproteinemic Neuropathies, and Others), by End User (Hospitals & Clinics, Diagnostic Centers, and Ambulatory Care Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Neurological disorder diagnostic tools are used for the diagnosis of various neurological disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and others. Neurological disorders can be diagnosed with the use of imaging and in vitro diagnostic techniques. Imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) are used to create detailed images of organs, bones, soft tissue, blood vessels, and other parts of body. Whereas, in-vitro diagnostic techniques include biopsy, biomarker, blood test, urine test, and genetic testing.
Market Dynamics
Technological innovations and developments in neurological disorder diagnosing devices are expected to drive the market growth. For instance, in 2017, Neusoft Medical Systems developed an innovative CT scanner NeuViz Prime CT Scanner and received the U.S. Food and Drug Administration approval for the system. Moreover in 2016, Koninklijke Philips N.V. launched IQon Spectral CT in Canada. IQon Spectral CT is a spectral detector CT, designed specifically for spectral imaging.
Key features of the study:
This report provides in-depth analysis of the global neurological disorder diagnostics market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neurological disorder diagnostics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics
The global neurological disorder diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurological disorder diagnostics market
Detailed Segmentation:
Global Neurological Disorder Diagnostics Market, By Technology:
Imaging
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging
Positron Emission Tomography (PET)
Single-photon Emission Computed Tomography (SPECT)
Near Infrared Spectroscopic Imaging (NIRS)
Electroencephalography (EEG)
Magnetoencephalography (MEG)
In Vitro Diagnostics
Biomarker
Biopsy
Others
Global Neurological Disorder Diagnostics Market, By Disease Indication:
Genetic Neurological Disorders
Alzheimer’s Disease (AD)
Parkinson’s Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease (HD)
Others
Immunological Neurological Disorders
Multiple Sclerosis
Others
Paraneoplastic Syndrome
Paraproteinemic Neuropathies
Others
Global Neurological Disorder Diagnostics Market, By End User:
Hospitals & Clinics
Diagnostic Centers
Ambulatory Care Centers
Global Neurological Disorder Diagnostics Market, By Region:
North America
By Technology:
Imaging
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging
Positron Emission Tomography (PET)
Single-photon Emission Computed Tomography (SPECT)
Near Infrared Spectroscopic Imaging (NIRS)
Electroencephalography (EEG)
Magnetoencephalography (MEG)
In Vitro Diagnostics
Biomarker
Biopsy
Others
By Disease Indication:
Genetic Neurological Disorders
Alzheimer’s Disease (AD)
Parkinson’s Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease (HD)
Others
Immunological Neurological Disorders
Multiple Sclerosis
Others
Paraneoplastic Syndrome
Paraproteinemic Neuropathies
Others
By End User:
Hospitals & Clinics
Diagnostic Centers
Ambulatory Care Centers
By Country:
U.S.
Canada
Latin America
By Technology:
Imaging
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging
Positron Emission Tomography (PET)
Single-photon Emission Computed Tomography (SPECT)
Near Infrared Spectroscopic Imaging (NIRS)
Electroencephalography (EEG)
Magnetoencephalography (MEG)
In Vitro Diagnostics
Biomarker
Biopsy
Others
By Disease Indication:
Genetic Neurological Disorders
Alzheimer’s Disease (AD)
Parkinson’s Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease (HD)
Others
Immunological Neurological Disorders
Multiple Sclerosis
Others
Paraneoplastic Syndrome
Paraproteinemic Neuropathies
Others
By End User:
Hospitals & Clinics
Diagnostic Centers
Ambulatory Care Centers
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Technology:
Imaging
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging
Positron Emission Tomography (PET)
Single-photon Emission Computed Tomography (SPECT)
Near Infrared Spectroscopic Imaging (NIRS)
Electroencephalography (EEG)
Magnetoencephalography (MEG)
In Vitro Diagnostics
Biomarker
Biopsy
Others
By Disease Indication:
Genetic Neurological Disorders
Alzheimer’s Disease (AD)
Parkinson’s Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease (HD)
Others
Immunological Neurological Disorders
Multiple Sclerosis
Others
Paraneoplastic Syndrome
Paraproteinemic Neuropathies
Others
By End User:
Hospitals & Clinics
Diagnostic Centers
Ambulatory Care Centers
By Country:
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia Pacific
By Technology:
Imaging
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging
Positron Emission Tomography (PET)
Single-photon Emission Computed Tomography (SPECT)
Near Infrared Spectroscopic Imaging (NIRS)
Electroencephalography (EEG)
Magnetoencephalography (MEG)
In Vitro Diagnostics
Biomarker
Biopsy
Others
By Disease Indication:
Genetic Neurological Disorders
Alzheimer’s Disease (AD)
Parkinson’s Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease (HD)
Others
Immunological Neurological Disorders
Multiple Sclerosis
Others
Paraneoplastic Syndrome
Paraproteinemic Neuropathies
Others
By End User:
Hospitals & Clinics
Diagnostic Centers
Ambulatory Care Centers
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Technology:
Imaging
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging
Positron Emission Tomography (PET)
Single-photon Emission Computed Tomography (SPECT)
Near Infrared Spectroscopic Imaging (NIRS)
Electroencephalography (EEG)
Magnetoencephalography (MEG)
In Vitro Diagnostics
Biomarker
Biopsy
Others
By Disease Indication:
Genetic Neurological Disorders
Alzheimer’s Disease (AD)
Parkinson’s Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease (HD)
Others
Immunological Neurological Disorders
Multiple Sclerosis
Others
Paraneoplastic Syndrome
Paraproteinemic Neuropathies
Others
By End User:
Hospitals & Clinics
Diagnostic Centers
Ambulatory Care Centers
By Country:
GCC
Israel
Rest of Middle East
Africa
By Technology:
Imaging
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging
Positron Emission Tomography (PET)
Single-photon Emission Computed Tomography (SPECT)
Near Infrared Spectroscopic Imaging (NIRS)
Electroencephalography (EEG)
Magnetoencephalography (MEG)
In Vitro Diagnostics
Biomarker
Biopsy
Others
By Disease Indication:
Genetic Neurological Disorders
Alzheimer’s Disease (AD)
Parkinson’s Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease (HD)
Others
Immunological Neurological Disorders
Multiple Sclerosis
Others
Paraneoplastic Syndrome
Paraproteinemic Neuropathies
Others
By End User:
Hospitals & Clinics
Diagnostic Centers
Ambulatory Care Centers
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Siemens Healthineers *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Koninklijke Philips N.V.
General Electric Company
Esaote SpA
NeuroLogica Corporation
Masimo Corporation
York Instruments Ltd
Neusoft Medical Systems
Canon Medical Systems Corporation
“*” marked represents similar segmentation in other categories in the respective section.